“These complexes dictate T cell activation or exhaustion, and their immunological codes can be used to design and clinically test a multitude of unprecedented therapeutic products based on precedented and specific mechanisms of T cell killing of antigen-presenting tumor cells or infected cells,” the company said in its announcement. Through the coupling of single-cell technologies with cellular and acellular antigen libraries, the company decodes CD4+ and CD8+ TCR-antigen specificity across selected T cell subsets from patients and from healthy individuals, Repertoire added. This allows its team to understand the presentation of antigens in disease, de-orphan T cell receptors in the context of single-cell phenotypes, and curate vast amounts of data to enable deep-learning computational prediction models, the company said in its announcement. Repertoire is harnessing the power of its DECODE technology that allows for in-depth characterization of the immune synapse with unprecedented precision.
Once you understand the immune code, you can design better medications to treat certain diseases, Cox said.
Now, Cox said, they can finally see what the T cells see in the body when they are engaged. For decades, researchers have understood the importance that T cells play in the immune response of the body. Particularly, Repertoire has the ability to decode human subject-derived antigen-T cell receptor (TCR) codes from healthy or diseased tissues. The reason, he said, is because of the abilities the company has to decode the immune synapses. In an interview with BioSpace this morning, Cox said the joining of the two companies will create what he believes will be “the” company in immune medicines. Repertoire is helmed by John Cox, who most recently led Biogen spinout Bioverativ, a hemophilia-focused company snapped up by Sanofi in 2018 for $11.6 billion. The new company is focused on tapping into the powers of the immune system to address numerous diseases. Repertoire Immune Medicines officially launched this morning following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines.
0 kommentar(er)
